Skip to content
Celexo Blacklabel
Advanced Triple-Source Technology for Comprehensive Skin Rejuvenation
In today’s advancing aesthetic landscape, addressing intrinsic and extrinsic skin aging requires intervention at the cellular and molecular level. ABio materials Co., headquartered in Korea, has developed Celexo Blacklabel a high-concentration formulation that combines three distinct exosome populations to deliver comprehensive regenerative signals targeting collagen degradation, cellular senescence, and matrix deterioration. Exclusively developed for use by licensed medical professionals, this US FDA-listed product reflects the company’s commitment to translating advanced biotechnology into clinical applications. This page explores the science, benefits, and clinical relevance of Celexo Blacklabel.
About ABio materials and Celexo Blacklabel
ABio materials Co. is a biotechnology-driven manufacturer specializing in advanced biomaterials for medical aesthetics, dermatology, and tissue regeneration. Operating pharmaceutical-grade facilities in Korea under ISO 13485 and GMP standards, the company transforms research into clinical-grade products that deliver measurable results. All products are US FDA listed, with ABio materials USA Inc. serving as the exclusive importer and distributor throughout North America.
Celexo Blacklabel is the company’s concentrated anti-aging formulation, engineered through a proprietary triple-source exosome system. The formulation combines plant stem cell-derived exosomes, fibroblast-conditioned exosomes, and adipose-derived stem cell exosomes at total concentrations reaching 30 billion particles per milliliter significantly higher than single-source products. Each exosome population provides complementary mechanisms: plant exosomes deliver antioxidant defense, fibroblast exosomes provide matrix remodeling signals, and adipose stem cell exosomes contribute tissue repair factors.
Core Values: Science First formulations grounded in peer-reviewed research and cellular biology. Professional Integrity serving only licensed professionals. Sustainable Innovation environmentally responsible manufacturing practices.
The Science Behind
Celexo Blacklabel
Celexo Blacklabel addresses skin aging through interconnected biological pathways activated by the triple exosome signaling system.
Collagen Synthesis:
Fibroblast-conditioned exosomes deliver growth factors that activate cellular signaling pathways, increasing Type I collagen expression by 300 to 400 percent in laboratory studies while enhancing collagen processing and Type III collagen synthesis for elastic fiber support.
Matrix Remodeling:
Exosome cargo regulates enzyme activity and increases protective inhibitors, supporting organized tissue remodeling. The formulation stimulates structural component synthesis, contributing to measurable dermal density improvements.
Cellular Function:
Adipose stem cell exosomes reduce cellular aging markers while supporting cellular recycling processes, enhancing energy production, and maintaining cellular health pathways.
Antioxidant Defense:
Plant-derived exosomes increase natural antioxidant enzyme expression, reduce damaging molecule formation, protect against environmental damage, and inhibit age-related molecular changes.
Key Benefits of Using Celexo Blacklabel
Multi-Pathway Regeneration:
Triple exosome system simultaneously addresses collagen loss, cellular aging, oxidative damage, and matrix deterioration through comprehensive signaling beyond single-mechanism approaches.
Quantified Performance:
Formulation demonstrates a 300 to 400 percent increase in collagen expression in controlled studies, supporting measurable improvements in skin density and wrinkle reduction.
Clinical Concentration:
Total exosome levels reaching 30 billion particles per milliliter represent significantly higher bioactive density, enabling measurable clinical outcomes.
Cumulative Effects:
Regular application supports sustained cellular signaling over time, with improvements continuing beyond initial treatment as tissue remodeling progresses.
Treatment Enhancement:
Amplifies outcomes when combined with microneedling, RF, PRP therapies, and laser treatments through synergistic mechanisms.
Quality Manufacturing:
Produced under ISO 13485 and GMP standards with US FDA listing, complete batch characterization, and pharmaceutical-grade specifications.
Clinical Applications of Celexo Blacklabel
Celexo Blacklabel is used by medical professionals in advanced anti-aging treatment protocols requiring measurable regenerative outcomes.
Common Use Cases:
Post-microneedling or RF microneedling enhancement at depths between 0.5 and 2.5mm
Adjunct to laser and RF treatments for thermal-induced collagen support
Combination with PRP or PRF for a synergistic growth factor environment
Intensive standalone anti-aging protocols with twice-daily application
Preventive maintenance programs supporting sustained collagen synthesis
Pre-event skin quality improvement for rapid visible enhancement
By targeting multiple aging mechanisms simultaneously, Celexo Blacklabel supports superior outcomes compared to single-pathway interventions, with results continuing to develop over treatment periods.
Ideal Use Environment
Celexo Blacklabel is not a consumer product and is intended exclusively for application by licensed professionals in medical or aesthetic clinical environments.
Recommended For Use By:
- Board-certified dermatologists specializing in regenerative dermatology
- Plastic and cosmetic surgeons
- Advanced aesthetic practitioners with exosome technology training
- Medical spas with physician oversight
- Clinical research teams investigating regenerative applications
Each formulation is manufactured under controlled conditions in Korea, adhering to rigorous standards for purity, safety, and consistency. The product requires refrigerated storage between 2 and 8 degrees Celsius. Complete technical documentation is available to licensed professionals.
Why Choose ABio materials as Your Manufacturing Partner
ABio materials Co. stands apart through commitment to scientific innovation, clinical excellence, and precision manufacturing in aesthetic medicine. Each formulation, including Celexo Blacklabel, results from rigorous research conducted in collaboration with biomedical experts to ensure maximum safety, efficacy, and clinical relevance.
With Korean-based production facilities operating under strict regulatory oversight, including ISO 13485 certification and GMP compliance, the company guarantees consistent quality and reliable delivery. All products are US FDA-listed. Each batch undergoes comprehensive testing: nanoparticle tracking analysis confirms particle concentration and size distribution, protein quantification verifies bioactive content, and flow cytometry confirms purity exceeding 90 percent. Microbiological testing per USP standards ensures safety compliance.
The triple-source exosome system represents significant technical complexity, with each population processed separately, characterized individually, then combined in proprietary ratios optimized for synergistic effects. Dedicated exclusively to licensed professionals through ABio materials USA Inc. for North American distribution, the company delivers evidence-based biomaterials that elevate patient outcomes. Technical support is available for protocol development and outcome measurement methodologies.
Frequently Asked Questions
What is Celexo Blacklabel made of?
Celexo Blacklabel is a proprietary triple-source exosome complex combining plant, fibroblast, and adipose-derived populations developed to support comprehensive anti-aging mechanisms. Full technical data is available to licensed professionals upon request.
Can patients purchase Celexo Blacklabel directly?
No. Celexo Blacklabel is not sold directly to consumers. It is intended solely for professional use in licensed medical or aesthetic environments.
How can providers obtain Celexo Blacklabel?
Clinics and licensed practitioners may contact ABio materials USA Inc., the exclusive North American distributor, via a-biousa.com to request information about clinical use, product availability, or distribution partnerships.
Is Celexo Blacklabel FDA-approved?
All ABio materials products are US FDA-listed and produced in pharmaceutical-grade facilities in Korea in accordance with applicable manufacturing standards. The product is not intended to diagnose, treat, or cure any medical condition.
Where is Celexo Blacklabel manufactured?
All production is conducted by ABio materials Co. in pharmaceutical-grade facilities in Korea under strict U.S. quality assurance and regulatory compliance protocols.
Leading the Future of Regenerative Aesthetics
As regenerative aesthetics continue to gain traction in clinical practice, ABio materials Co. stands out as a leader in developing safe, science-driven biomaterials. Celexo Blacklabel reflects this mission by offering a biologically intelligent, clinically effective solution for aesthetic professionals committed to enhancing patient outcomes.
To learn more about integrating Celexo Blacklabel into your practice or to explore collaboration opportunities, visit a-biousa.com.
Contact Us
We welcome inquiries from partners, distributors, and industry professionals worldwide. Whether you are interested in our product portfolio, ODM/OEM collaboration, or research support, our team is committed to providing clear, timely, and knowledgeable assistance. Reach out to learn how our bio-material technologies and exosome expertise can support your clinical, aesthetic, or research goals.
Get in touch
